Date: 2012-03-19
Type of information: R&D agreement
Compound:
Company: UCB (Belgium) Oxford University (UK)
Therapeutic area: Immunological diseases - Neurological diseases
Type agreement: R&D
Action mechanism:
Disease: serious diseases in immunology and neurology
Details: UCB Pharma and Oxford University have agreed to collaborate on cutting-edge pharmaceutical research projects, enabling scientists from industry and academia to work together to develop innovative medicines to treat serious diseases in immunology and neurology. These combined resources and expertise will give the best possible chance of turning innovative research into new medicines for patients, an area identified as a priority in the recent government Strategy for UK Life Sciences.
A steering committee of UCB and Oxford University representatives will oversee the collaboration via regular meetings to scope out and monitor new projects. Between five and 10 projects will be selected for investigation over the course of the three-year agreement.
Financial terms: The Oxford-UCB partnership will be funded by a contribution of £3.6 million from UCB and will run over 3 years.
Latest news:
